ONVO · Organovo Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $144.0K | $109.0K | $370.0K | $1.50M | $0 | $2.20M |
| Cost of Revenue | $5.0K | - | - | - | $0 | $300.0K |
| Gross Profit | $139.0K | - | - | - | $0 | $1.90M |
| R&D | $5.03M | $5.50M | $8.88M | $3.32M | $1.10M | $5.28M |
| SG&A | $7.73M | $9.70M | $9.22M | $9.66M | $15.72M | $18.06M |
| Total Operating Expenses | $12.76M | $15.20M | $18.10M | $12.98M | $16.83M | $23.67M |
| D&A | $266.0K | $280.0K | $293.0K | $142.0K | $41.0K | $1.14M |
| Operating Income | ($12.62M) | ($15.09M) | ($17.73M) | ($11.48M) | ($16.83M) | ($21.48M) |
| Interest Expense | $10.0K | - | - | - | - | - |
| Income Tax | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K |
| Net Income | ($2.49M) | ($14.67M) | ($17.26M) | ($11.45M) | ($16.83M) | ($18.71M) |
| EPS - Basic | ($1.70) | ($1.60) | ($1.98) | - | - | - |
| EPS - Diluted | ($1.70) | ($1.60) | ($1.32) | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.31M | $2.90M | $15.30M | $28.68M | $37.36M | $27.36M |
| Accounts Receivable | $30.0K | $33.0K | $152.0K | - | $0 | $111.0K |
| Inventory | $0 | $0 | - | - | - | $0 |
| Accounts Payable | $1.64M | $627.0K | $331.0K | $415.0K | $281.0K | $720.0K |
| Current Assets | $12.13M | $3.94M | $17.05M | $29.53M | $38.40M | $28.32M |
| Total Assets | $14.65M | $6.35M | $20.31M | $33.30M | $39.92M | $28.44M |
| Current Liabilities | $3.74M | $1.86M | $3.67M | $1.38M | $721.0K | $1.81M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $4.16M | $2.75M | $4.98M | $3.09M | - | $1.81M |
| Stockholders' Equity | $10.49M | $3.60M | $15.33M | $30.21M | $39.20M | $26.63M |
| Retained Earnings | ($342.16M) | ($339.67M) | ($325.00M) | ($307.74M) | ($296.29M) | ($279.46M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.46M) | ($14.65M) | ($12.41M) | ($8.45M) | ($13.32M) | ($14.88M) |
| Investing Cash Flow | $9.03M | $816.0K | ($966.0K) | ($409.0K) | ($393.0K) | $747.0K |
| Financing Cash Flow | $8.85M | $1.44M | $0 | $205.0K | $23.84M | $4.93M |
| CapEx | $13.0K | $42.0K | $396.0K | $409.0K | $405.0K | $0 |
| Free Cash Flow | ($9.47M) | ($14.70M) | ($12.80M) | ($8.86M) | ($13.73M) | ($14.88M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 96.5% | - | - | - | - | 86.3% |
| Operating margin | -8761.1% | -13840.4% | -4792.2% | -765.3% | - | -977.9% |
| EBITDA margin | -8576.4% | -13583.5% | -4713.0% | -755.8% | - | -925.9% |
| Net margin | -1727.8% | -13459.6% | -4664.6% | -763.2% | - | -852.0% |
| Free cash flow margin | -6579.2% | -13481.7% | -3460.5% | -590.8% | - | -677.7% |
| FCF / Net income | 3.81 | 1.00 | 0.74 | 0.77 | 0.82 | 0.80 |
| R&D / Revenue | 3489.6% | 5044.0% | 2401.4% | 221.3% | - | 240.6% |
| SG&A / Revenue | 5368.1% | 8896.3% | 2490.8% | 643.9% | - | 822.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -17.0% | -231.1% | -85.0% | -34.4% | -42.2% | -65.8% |
| Return on equity | -23.7% | -407.4% | -112.6% | -37.9% | -42.9% | -70.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 |
| Quick ratio | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 |
| Cash ratio | 3.03 | 1.56 | 4.17 | 20.73 | 51.82 | 15.11 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1261.6x | - | - | - | - | - |
| Equity multiplier | 1.40 | 1.76 | 1.33 | 1.10 | 1.02 | 1.07 |
| Liabilities / Assets | 0.28 | 0.43 | 0.25 | 0.09 | - | 0.06 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.02 | 0.02 | 0.05 | 0.00 | 0.08 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 76d | 111d | 150d | - | - | 18d |
| Days inventory outstanding | 0d | - | - | - | - | 0d |
| Days payable outstanding | 120012d | - | - | - | - | 876d |
| Cash conversion cycle | -119936d | - | - | - | - | -858d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 32.1% | -70.5% | -75.3% | - | -100.0% | -52.3% |
| Revenue CAGR (3y) | -54.2% | - | -44.8% | -31.2% | - | -19.6% |
| Revenue CAGR (5y) | -42.0% | -52.7% | -39.6% | -18.7% | - | 30.9% |
| Gross profit growth (YoY) | - | - | - | - | - | -53.8% |
| Operating income growth (YoY) | 16.4% | 14.9% | -54.5% | 31.8% | 21.6% | 21.3% |
| Net income growth (YoY) | 83.0% | 15.0% | -50.8% | 32.0% | 10.1% | 29.8% |
| EPS growth (YoY) | -6.2% | -21.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 35.5% | -14.8% | -44.5% | 35.4% | 7.8% | 48.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 191.4% | -76.5% | -49.3% | -22.9% | 47.2% | -26.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-03-31.
Product / service
$263.0K totalRoyalty$119.0K · 45.2%
Sales Based Royalties$119.0K · 45.2%
Product$25.0K · 9.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-20.98
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ORGANOVO HOLDINGS against the 5 most active filers in the same SIC group.